Status:
COMPLETED
Epileptic Seizure in Epilepsy Patients After SARS-CoV-2 Vaccination
Lead Sponsor:
Xijing Hospital
Conditions:
Epileptic Seizures Related to Drugs
SARS-CoV-2 Acute Respiratory Disease
Eligibility:
All Genders
3+ years
Brief Summary
Background and Objectives: Seizure attack is one of adverse effects of vaccination in epileptic patients, the risk of which after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inoculati...
Eligibility Criteria
Inclusion
- Male or female participants
- Have a diagnosis of epilepsy by the end of the study
- Have received at least one dose of inactive SARS-Cov-2 vaccine (Sinovac Life Sciences and Sinopharm Group)
Exclusion
- Non-epilepsy patients vaccinated with inactive SARS-Cov-2 vaccine
- Epilepsy patients administrated with non-inactive vaccine
- Unvaccinated epilepsy patients
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05341713
Start Date
January 1 2022
End Date
April 1 2022
Last Update
April 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital
Xi'an, Shaanxi, China, 710000